Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study

Abstract Background We are witnessing an exponential increase in the number of randomized controlled trials (RCTs) reported from mainland China. The increase is particularly notable in the field of new generation antidepressants and antipsychotics. Several previous studies have raised doubts regardi...

Full description

Bibliographic Details
Main Authors: Zheng Tong, Fangzhou Li, Yusuke Ogawa, Norio Watanabe, Toshi A. Furukawa
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Medical Research Methodology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12874-018-0554-2
_version_ 1818599674037141504
author Zheng Tong
Fangzhou Li
Yusuke Ogawa
Norio Watanabe
Toshi A. Furukawa
author_facet Zheng Tong
Fangzhou Li
Yusuke Ogawa
Norio Watanabe
Toshi A. Furukawa
author_sort Zheng Tong
collection DOAJ
description Abstract Background We are witnessing an exponential increase in the number of randomized controlled trials (RCTs) reported from mainland China. The increase is particularly notable in the field of new generation antidepressants and antipsychotics. Several previous studies have raised doubts regarding their quality. However, the quality of most recent RCTs published in China may have improved. Methods We searched RCTs that examined new generation antidepressants and antipsychotics published between 2013 and 2016 in the China National Knowledge Infrastructure (CNKI), the largest database of scientific publications in China. We interviewed the authors of a random subset of the identified references. We assessed the methodological rigor of each study based on the published reports and telephone interviews with the authors using six methodological domains adapted from the Cochrane’s risk of bias tool. Results The final sample consisted of 138 studies, for which we interviewed 58 authors; the authors of 51 studies declined the interview, and the authors of 29 studies could not be contacted. The 51 studies with refused interviews were significantly less likely to be reported from university-affiliated hospitals and were less likely to be published in Chinese core journals. Based on the published reports, most of the 58 studies were assessed to be at unclear risk of bias in most methodological domains. After the interview, only 10 studies were assessed to be at low risk of bias for sequence generation and allocation concealment. Assuming that the studies for which the authors declined interviews had an unclear risk, the proportion of RCTs at low risk of bias in both sequence generation and allocation concealment was 9.2% (10/109, 95% confidence interval [CI]: 5.0 to 16.2). The interviews indicated that the studies were at high risk of bias for most of the other domains. Conclusion In general, RCTs that evaluate new generation antidepressants or antipsychotics and are indexed in the CNKI continue to be of low quality. When conducting systematic reviews and meta-analyses in this field, it would be wise to include a specialist from China as a coresearcher to help assess the risk of bias in the identified studies.
first_indexed 2024-12-16T12:23:20Z
format Article
id doaj.art-3e2fc369d7404a2589f5eee389ef998d
institution Directory Open Access Journal
issn 1471-2288
language English
last_indexed 2024-12-16T12:23:20Z
publishDate 2018-09-01
publisher BMC
record_format Article
series BMC Medical Research Methodology
spelling doaj.art-3e2fc369d7404a2589f5eee389ef998d2022-12-21T22:31:54ZengBMCBMC Medical Research Methodology1471-22882018-09-0118111110.1186/s12874-018-0554-2Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview studyZheng Tong0Fangzhou Li1Yusuke Ogawa2Norio Watanabe3Toshi A. Furukawa4Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public HealthDepartment of Neurology, Kyoto University Graduate School of MedicineDepartment of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public HealthDepartment of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public HealthDepartment of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public HealthAbstract Background We are witnessing an exponential increase in the number of randomized controlled trials (RCTs) reported from mainland China. The increase is particularly notable in the field of new generation antidepressants and antipsychotics. Several previous studies have raised doubts regarding their quality. However, the quality of most recent RCTs published in China may have improved. Methods We searched RCTs that examined new generation antidepressants and antipsychotics published between 2013 and 2016 in the China National Knowledge Infrastructure (CNKI), the largest database of scientific publications in China. We interviewed the authors of a random subset of the identified references. We assessed the methodological rigor of each study based on the published reports and telephone interviews with the authors using six methodological domains adapted from the Cochrane’s risk of bias tool. Results The final sample consisted of 138 studies, for which we interviewed 58 authors; the authors of 51 studies declined the interview, and the authors of 29 studies could not be contacted. The 51 studies with refused interviews were significantly less likely to be reported from university-affiliated hospitals and were less likely to be published in Chinese core journals. Based on the published reports, most of the 58 studies were assessed to be at unclear risk of bias in most methodological domains. After the interview, only 10 studies were assessed to be at low risk of bias for sequence generation and allocation concealment. Assuming that the studies for which the authors declined interviews had an unclear risk, the proportion of RCTs at low risk of bias in both sequence generation and allocation concealment was 9.2% (10/109, 95% confidence interval [CI]: 5.0 to 16.2). The interviews indicated that the studies were at high risk of bias for most of the other domains. Conclusion In general, RCTs that evaluate new generation antidepressants or antipsychotics and are indexed in the CNKI continue to be of low quality. When conducting systematic reviews and meta-analyses in this field, it would be wise to include a specialist from China as a coresearcher to help assess the risk of bias in the identified studies.http://link.springer.com/article/10.1186/s12874-018-0554-2Randomized controlled trialsAntidepressive agentsAntipsychotic agentsRisk of biasResearch integrityChina
spellingShingle Zheng Tong
Fangzhou Li
Yusuke Ogawa
Norio Watanabe
Toshi A. Furukawa
Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
BMC Medical Research Methodology
Randomized controlled trials
Antidepressive agents
Antipsychotic agents
Risk of bias
Research integrity
China
title Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
title_full Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
title_fullStr Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
title_full_unstemmed Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
title_short Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study
title_sort quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the china national knowledge infrastructure cnki a literature and telephone interview study
topic Randomized controlled trials
Antidepressive agents
Antipsychotic agents
Risk of bias
Research integrity
China
url http://link.springer.com/article/10.1186/s12874-018-0554-2
work_keys_str_mv AT zhengtong qualityofrandomizedcontrolledtrialsofnewgenerationantidepressantsandantipsychoticsidentifiedinthechinanationalknowledgeinfrastructurecnkialiteratureandtelephoneinterviewstudy
AT fangzhouli qualityofrandomizedcontrolledtrialsofnewgenerationantidepressantsandantipsychoticsidentifiedinthechinanationalknowledgeinfrastructurecnkialiteratureandtelephoneinterviewstudy
AT yusukeogawa qualityofrandomizedcontrolledtrialsofnewgenerationantidepressantsandantipsychoticsidentifiedinthechinanationalknowledgeinfrastructurecnkialiteratureandtelephoneinterviewstudy
AT noriowatanabe qualityofrandomizedcontrolledtrialsofnewgenerationantidepressantsandantipsychoticsidentifiedinthechinanationalknowledgeinfrastructurecnkialiteratureandtelephoneinterviewstudy
AT toshiafurukawa qualityofrandomizedcontrolledtrialsofnewgenerationantidepressantsandantipsychoticsidentifiedinthechinanationalknowledgeinfrastructurecnkialiteratureandtelephoneinterviewstudy